ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion

[1]  A. Welm,et al.  Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies. , 2024, Cancer cell.

[2]  M. Hashimoto,et al.  Harnessing CD8 T cell responses using PD-1-IL-2 combination therapy. , 2023, Trends in cancer.

[3]  A. Copik,et al.  Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies , 2023, Journal for ImmunoTherapy of Cancer.

[4]  E. Wherry,et al.  CD8+ T cells in the cancer-immunity cycle. , 2023, Immunity.

[5]  Hong Zhang,et al.  A membrane-associated MHC-I inhibitory axis for cancer immune evasion , 2023, Cell.

[6]  C. Fegan,et al.  Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy , 2023, Cell.

[7]  J. C. Love,et al.  Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity , 2023, Cell.

[8]  T. Rispens,et al.  The unique properties of IgG4 and its roles in health and disease , 2023, Nature Reviews Immunology.

[9]  Catherine J. Wu,et al.  Dynamics and specificities of T cells in cancer immunotherapy , 2023, Nature Reviews Cancer.

[10]  P. Sharma,et al.  Immune checkpoint therapy—current perspectives and future directions , 2023, Cell.

[11]  Stacy L. Gelhaus,et al.  Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment , 2023, Cell.

[12]  B. Monk,et al.  Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. , 2023, The New England journal of medicine.

[13]  Mingyao Liu,et al.  Enhancing the antitumor immunity of T cells by engineering the lipid-regulatory site of the TCR/CD3 complex. , 2022, Cancer immunology research.

[14]  B. Neel,et al.  Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy , 2022, Cancer discovery.

[15]  Zhonghui Tang,et al.  The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes , 2022, Cell.

[16]  B. Malissen,et al.  Kinetic proofreading through the multi-step activation of the ZAP70 kinase underlies early T cell ligand discrimination , 2022, Nature Immunology.

[17]  G. Hummer,et al.  Structure of a fully assembled tumor-specific T cell receptor ligated by pMHC , 2022, Cell.

[18]  M. Gonen,et al.  PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. , 2022, The New England journal of medicine.

[19]  L. Gao,et al.  PD‐1 mediates decidual γδ T cells cytotoxicity during recurrent pregnancy loss , 2022, American journal of reproductive immunology.

[20]  A. Utsunomiya,et al.  Identification and characterization of a novel enhancer in the HTLV-1 proviral genome , 2022, Nature Communications.

[21]  David R. Liu,et al.  Prioritization of autoimmune disease-associated genetic variants that perturb regulatory element activity in T cells , 2022, Nature Genetics.

[22]  R. Germain,et al.  Tuning T cell receptor sensitivity through catch bond engineering , 2022, Science.

[23]  Thomas D. Wu,et al.  Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses , 2022, Immunity.

[24]  Paul J. Hoffman,et al.  Dictionary learning for integrative, multimodal and scalable single-cell analysis , 2022, bioRxiv.

[25]  B. Helmink,et al.  Hallmarks of response, resistance, and toxicity to immune checkpoint blockade , 2022, Cell.

[26]  Xueda Hu,et al.  Pan-cancer single-cell landscape of tumor-infiltrating T cells , 2021, Science.

[27]  M. Ogris,et al.  CD47-targeted cancer immunogene therapy: Secreted SIRPα-Fc fusion protein eradicates tumors by macrophage and NK cell activation , 2021, Molecular therapy oncolytics.

[28]  Junzhi Wang,et al.  Development of a novel reporter gene assay to evaluate antibody-dependent cellular phagocytosis for anti-CD20 therapeutic antibodies. , 2021, International immunopharmacology.

[29]  Junzhi Wang,et al.  A reporter gene assay for determining the biological activity of therapeutic antibodies targeting TIGIT , 2021, Acta pharmaceutica Sinica. B.

[30]  G. Long,et al.  Immune checkpoint inhibitors in melanoma , 2021, The Lancet.

[31]  J. Clohessy,et al.  Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy , 2021, Cell.

[32]  G. Eberl,et al.  Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer , 2021, Cell.

[33]  A. Horuzsko,et al.  Humanized Mouse Model as a Novel Approach in the Assessment of Human Allogeneic Responses in Organ Transplantation , 2021, Frontiers in Immunology.

[34]  K. Gaus,et al.  Canonical T cell receptor docking on peptide–MHC is essential for T cell signaling , 2021, Science.

[35]  H. Tien,et al.  Distinct clinical and biological characteristics of acute myeloid leukemia with higher expression of long noncoding RNA KIAA0125 , 2020, Annals of Hematology.

[36]  Catherine C L Wong,et al.  Multiple Signaling Roles of CD3ε and Its Application in CAR-T Cell Therapy , 2020, Cell.

[37]  S. Günther,et al.  Noncanonical binding of Lck to CD3ε promotes TCR signaling and CAR function , 2020, Nature Immunology.

[38]  T. Harrer,et al.  Human Fcγ-receptor IIb modulates pathogen-specific versus self-reactive antibody responses in lyme arthritis , 2020, eLife.

[39]  D. Longo,et al.  Minimal PD-1 expression in mouse and human NK cells under diverse conditions. , 2020, The Journal of clinical investigation.

[40]  Peng Jiang,et al.  Large-scale public data reuse to model immunotherapy response and resistance , 2020, Genome Medicine.

[41]  Shujie Liao,et al.  PDL1 blockage increases fetal resorption and Tfr cells but does not affect Tfh/Tfr ratio and B-cell maturation during allogeneic pregnancy , 2020, Cell Death & Disease.

[42]  D. Schadendorf,et al.  Tertiary lymphoid structures improve immunotherapy and survival in melanoma , 2020, Nature.

[43]  Hong-Fu Xie,et al.  Etanercept biosimilar (recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial , 2019, Archives of Dermatological Research.

[44]  G. Freeman,et al.  Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.

[45]  W. Schamel,et al.  Anti-CD3 Fab Fragments Enhance Tumor Killing by Human γδ T Cells Independent of Nck Recruitment to the γδ T Cell Antigen Receptor , 2018, Front. Immunol..

[46]  T. Chan,et al.  Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab , 2017, Cell.

[47]  T. Graeber,et al.  Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells , 2016, Cancer Immunology Research.

[48]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.

[49]  A. Gingras,et al.  Combinatorial proteomic analysis of intercellular signaling applied to the CD28 T-cell costimulatory receptor , 2015, Proceedings of the National Academy of Sciences.

[50]  J. Liu,et al.  Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity , 2014, Proceedings of the National Academy of Sciences.

[51]  M. Wunderlich,et al.  OKT3 prevents xenogeneic GVHD and allows reliable xenograft initiation from unfractionated human hematopoietic tissues. , 2014, Blood.

[52]  A. Palucka,et al.  Development and function of human innate immune cells in a humanized mouse model , 2014, Nature Biotechnology.

[53]  A. Órfão,et al.  Relevance of Nck–CD3ε Interaction for T Cell Activation In Vivo , 2014, The Journal of Immunology.

[54]  O. Boyman,et al.  Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection. , 2013, Cell reports.

[55]  C. Benoist,et al.  Differential Response of Regulatory and Conventional CD4+ Lymphocytes to CD3 Engagement: Clues to a Possible Mechanism of Anti-CD3 Action? , 2013, The Journal of Immunology.

[56]  Mark M. Davis,et al.  Distinct T cell receptor signaling pathways drive proliferation and cytokine production in T cells , 2013, Nature Immunology.

[57]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[58]  K. Coombes,et al.  Robust Gene Expression Signature from Formalin-Fixed Paraffin-Embedded Samples Predicts Prognosis of Non–Small-Cell Lung Cancer Patients , 2011, Clinical Cancer Research.

[59]  Anne-Marie Cleton-Jansen,et al.  Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents , 2011, Clinical Cancer Research.

[60]  R Eils,et al.  Comparison of performance of one-color and two-color gene-expression analyses in predicting clinical endpoints of neuroblastoma patients , 2010, The Pharmacogenomics Journal.

[61]  M. Friedrich,et al.  T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells , 2010, Proceedings of the National Academy of Sciences.

[62]  J. Daily,et al.  Trypanosoma cruzi Triggers an Early Type I IFN Response In Vivo at the Site of Intradermal Infection1 , 2009, The Journal of Immunology.

[63]  L. Staudt,et al.  Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.

[64]  E. Reinherz,et al.  Structural and functional evidence that Nck interaction with CD3epsilon regulates T-cell receptor activity. , 2008, Journal of molecular biology.

[65]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[66]  R. Wagner,et al.  Reciprocal Regulation of SH3 and SH2 Domain Binding via Tyrosine Phosphorylation of a Common Site in CD3ε1 , 2007, The Journal of Immunology.

[67]  J. Mesirov,et al.  From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005 .

[68]  S. Harrison,et al.  Crystal structure of a human CD3-ε/δ dimer in complex with a UCHT1 single-chain antibody fragment , 2004 .

[69]  A. Weiss,et al.  Jurkat T cells and development of the T-cell receptor signalling paradigm , 2004, Nature Reviews Immunology.

[70]  Balbino Alarcón,et al.  Recruitment of Nck by CD3ϵ Reveals a Ligand-Induced Conformational Change Essential for T Cell Receptor Signaling and Synapse Formation , 2002, Cell.

[71]  G. Aversa,et al.  INDUCTION OF LONG‐TERM SPECIFIC TOLERANCE TO ALLOGRAFTS IN RATS BY THERAPY WITH AN ANTI‐CD3-LIKE MONOCLONAL ANTIBODY , 1993, Transplantation.

[72]  P. Beverley,et al.  Human T lymphocyte activation by monoclonal antibodies; OKT3, but not UCHT1, triggers mitogenesis via an interleukin 2-dependent mechanism. , 1984, Journal of immunology.

[73]  OUP accepted manuscript , 2021, Nucleic Acids Research.

[74]  Z. Guo,et al.  T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[75]  R. N. Brogden,et al.  Muromonab CD3 , 2012, Drugs.